Results 101 to 110 of about 5,258 (215)

Characterizing Apixaban Pharmacokinetics Through Physiologically‐Based Pharmacokinetic Modeling: Critical Role of Biliary Secretion and Enterohepatic Circulation in Humans

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Apixaban, a factor Xa inhibitor, is a direct oral anticoagulant with a well‐balanced elimination; it is eliminated evenly via feces, urine (with no active secretion), and as metabolites after oral administration. The common understanding is that biliary secretion and enterohepatic circulation (EHC) of apixaban are limited in humans, and that ...
Toshiaki Tsuchitani   +3 more
wiley   +1 more source

Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis   +3 more
wiley   +1 more source

Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide

open access: yesDrug Design, Development and Therapy, 2015
Hyeon-Uk Jeong,1 Mihwa Kwon,2 Yongnam Lee,3 Ji Seok Yoo,3 Dae Hee Shin,3 Im-Sook Song,2 Hye Suk Lee1 1College of Pharmacy, The Catholic University of Korea, Bucheon 420-743, Korea; 2College of Pharmacy and Research Institute of Pharmaceutical Sciences ...
Jeong HU   +6 more
doaj  

Organic anion transporters and their influence on the toxicity of β-lactam antibiotics

open access: yesБезопасность и риск фармакотерапии, 2018
This review article describes the classification and mechanism of action of organic anion transporters (OAT). The influence of certain members of this family of transporters on the pharmacokinetics of β-lactam antibiotics.
V. A. Evteev   +5 more
doaj  

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [PDF]

open access: yes, 2017
Background: Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Aghajanian, C   +116 more
core   +1 more source

Expression of OAT1 and OAT3 in differentiating proximal tubules of the mouse kidney.

open access: yesHistology and histopathology, 2009
Organic anion transporter 1 (OAT1) and OAT3 in the proximal tubules (PT) of the kidney play important roles in the elimination of harmful endogenous compounds and xenobiotics from the body. We investigated the temporal and spatial expression of OAT1 and OAT3 in the differentiating PT in mouse kidney.
Hwang, Jin-Sun   +4 more
openaire   +3 more sources

Ecogenetics of mercury: From genetic polymorphisms and epigenetics to risk assessment and decision‐making [PDF]

open access: yes, 2014
The risk assessment of mercury (Hg), in both humans and wildlife, is made challenging by great variability in exposure and health effects. Although disease risk arises following complex interactions between genetic (“nature”) and environmental (“nurture”)
Arai   +104 more
core   +1 more source

Glutamate cycling may drive organic anion transport on the basal membrane of human placental syncytiotrophoblast

open access: yes, 2015
The organic anion transporter OAT4 (SLC22A11) and organic anion transporting polypeptide OATP2B1 (SLCO2B1) are expressed in the basal membrane of the placental syncytiotrophoblast.
Brooks, S.   +6 more
core   +1 more source

Bezafibrate–mizoribine interaction: Involvement of organic anion transporters OAT1 and OAT3 in rats

open access: yesEuropean Journal of Pharmaceutical Sciences, 2016
A patient with rheumatoid arthritis developed rhabdomyolysis while undergoing treatment with mizoribine concomitantly with bezafibrate. The symptoms rapidly disappeared and laboratory test results normalized when she discontinued the two drugs. The purpose of the present study was to elucidate the transporter-mediated molecular pharmacokinetic ...
Yuan Feng   +10 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy